PMC2018 Mobile Header 300x76

New Horizons in Dyslipidemia Management in Primary Care

Type: Accredited Symposia
Thursday May 10
6:00pm to 7:00pm
Location: Symposia C

  • Description

    Learning Objectives
    • Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently competed clinical trials.
    • Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease.
    • Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies.
    • Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics.

    Accreditation Statement:
    This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.

    Industry Support
    This program was supported in part by an educational grant from Amgen.
  • Speakers